1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 33 pages

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016’, provides an overview of the Elephantiasis (Lymphatic Filariasis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis)
- The report reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Elephantiasis (Lymphatic Filariasis) therapeutics and enlists all their major and minor projects
- The report assesses Elephantiasis (Lymphatic Filariasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Elephantiasis (Lymphatic Filariasis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Elephantiasis (Lymphatic Filariasis) Overview 6
Therapeutics Development 7
Pipeline Products for Elephantiasis (Lymphatic Filariasis) - Overview 7
Pipeline Products for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis 8
Elephantiasis (Lymphatic Filariasis) - Therapeutics under Development by Companies 9
Elephantiasis (Lymphatic Filariasis) - Therapeutics under Investigation by Universities/Institutes 10
Elephantiasis (Lymphatic Filariasis) - Pipeline Products Glance 11
Early Stage Products 11
Elephantiasis (Lymphatic Filariasis) - Products under Development by Companies 12
Elephantiasis (Lymphatic Filariasis) - Products under Investigation by Universities/Institutes 13
Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development 14
Anacor Pharmaceuticals, Inc. 14
Eisai Co., Ltd. 15
Johnson and Johnson 16
Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Molecule Type 20
Drug Profiles 22
filariasis vaccine - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
flubendazole - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
IIC-942A001 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
IIC-950A001 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
lymphatic filariasis vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
S-0112091 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Small Molecule for Lymphatic Filariasis - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Small Molecules for Lymphatic Filariasis and Onchocerciasis - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Small Molecules for Nematodal Diseases - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H1 2016 7
Number of Products under Development for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Products under Investigation by Universities/Institutes, H1 2016 13
Elephantiasis (Lymphatic Filariasis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 14
Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co., Ltd., H1 2016 15
Elephantiasis (Lymphatic Filariasis) - Pipeline by Johnson and Johnson, H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21

List of Figures
Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H1 2016 7
Number of Products under Development for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
umber of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Molecule Types, H1 2016 20
Number of Products by Stage and Molecule Types, H1 2016 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.